Does a 66-year-old man with documented primary hypogonadism and a normal prostate-specific antigen require a follow‑up with a urologist?

Urologic Follow-Up for Primary Hypogonadism with Normal PSA

A 66-year-old man with documented primary hypogonadism and normal PSA does not require routine urologic referral at baseline, but will need urologic consultation if specific monitoring thresholds are exceeded during testosterone therapy.

Initial Assessment and Monitoring Framework

Since this patient has primary hypogonadism (testicular failure) with a normal PSA, he does not need immediate urologic referral before starting testosterone therapy. However, structured monitoring with clear urologic referral triggers is mandatory once testosterone replacement begins 1, 2.

Baseline Requirements Before Starting Testosterone

For men ≥40 years with baseline PSA >0.6 ng/mL, perform:

• Digital rectal examination (DRE)
• PSA measurement
• Document baseline voiding symptoms 1, 3

If baseline PSA is >4.0 ng/mL or DRE reveals abnormalities (nodules, asymmetry, induration), obtain urologic consultation before initiating testosterone 3.

Specific Triggers for Urologic Referral During Treatment

Obtain urologic consultation if any of the following occur 1, 2:

PSA-Related Triggers

1. PSA increase >1.4 ng/mL within any 12-month period after starting testosterone 1, 2
2. Confirmed PSA >4.0 ng/mL at any time 2
3. PSA velocity >0.4 ng/mL per year (only applicable if PSA data available for >2 years) 1
4. For men with baseline PSA 2.6-4.0 ng/mL: consider both the absolute PSA level AND a confirmed increase >1.4 ng/mL when deciding on referral 2

Physical Examination Triggers

• Any prostatic abnormality detected on DRE (nodule, induration, asymmetry, increased firmness) 1, 2

Urinary Symptom Triggers

• American Urological Association Symptom Index (AUA/IPSS) score >19 1

Monitoring Schedule

Follow this timeline for PSA and DRE monitoring 1, 2:

• 3-6 months after initiating testosterone therapy
• Annually thereafter (or every 6-12 months per some guidelines 4)
• Check hematocrit at the same intervals (stop therapy if >54%) 1, 2

Important Clinical Caveats

Confirm PSA Elevations

PSA measurements have significant test-retest variability. Always confirm elevated PSA by repeating the test before urologic referral 2, 1. Transient elevations may result from:

• Prostatitis (treat with antibiotics, which can lower PSA ~30%) 1
• Benign prostatic hyperplasia
• Prostate trauma
• Urinary tract infections
• Assay variability 2

Expected PSA Changes on Testosterone

Testosterone therapy typically increases PSA by an average of 0.3-0.44 ng/mL 2, 1. The 90% confidence limit for PSA change over 3-6 months is 1.4 ng/mL 1—increases beyond this are unusual and warrant investigation.

Primary Hypogonadism Considerations

Men with primary testicular failure (elevated LH, low testosterone) have decompensated hypogonadism requiring testosterone replacement 5. These patients need the full spectrum of hypogonadism management, including monitoring for osteoporosis, anemia, and metabolic effects—not just prostate surveillance.

In summary: No immediate urologic referral is needed, but establish clear monitoring protocols with specific PSA and DRE thresholds that trigger urologic consultation during testosterone therapy.